Methods to identify USP1 deubiquitinating enzyme complex inhibitors
AssigneeDana-Farber Cancer Institute, Inc.
InventorAlan D. D'Andrea
Life of this patent
Estimating the term…
Loading patent…
AssigneeDana-Farber Cancer Institute, Inc.
InventorAlan D. D'Andrea
Estimating the term…
The invention provides methods used to identify new inhibitors of USP1 deubiquitinase. The inhibitors can be identified by contacting isolated USP1 with a test compound in the presence of monoubiquitinated proliferating cell nuclear antigen (PCNA), monoubiquitinated human Fanconi anemia group D2 (FANCD2), or ubiquitin-7-amido-4-methylcoumarin, and detecting the deubiquitination of said PCNA, FANCD2, or ubiquitin-7-amido-4-methylcoumarin using an antibody or fluorescence, wherein a decrease in the deubiquitination of said PCNA, FANCD2, or ubiquitin-7-amido-4-methylcoumarin in the presence of the test compound relative to the absence of the test compound identifies said test compound as an inhibitor of USP1 deubiquitinase.
An in vitro, biochemical method of identifying an inhibitor of ubiquitin specific protease 1(USP1) comprising:
An in vitro, biochemical method of identifying an inhibitor of USP1 comprising:
Dependencies are inferred from the claim text.